Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma.

Annie N M WongMolly WilliamsDonna MilneKortnye MorrisPeter LauOdette SpruytSonia FullertonGrant McArthur

Published in: Asia-Pacific journal of clinical oncology (2017)

Patients with poor baseline PS have a significantly lower OS and reduced response to anti-PD1. Further quality of life and palliative care research is needed.

Keyphrases

palliative care
end stage renal disease
advanced cancer
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
type diabetes
patient reported outcomes
adipose tissue
skeletal muscle
weight loss